Silence Therapeutics Plc American Depository Share SLN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-03T14:44:08.474Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T14:38:28.125134406Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-03T14:44:07.814439+00:00
Silence Therapeutics Plc American Depository Share options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 20.15 | 6.6% | 2.0% | 18.55 | 40.5% | 9.5% |
| 25Δ | 19.86 | 6.6% | 1.2% | 18.88 | 42.6% | 8.8% |
| 30Δ | 19.70 | 8.7% | 1.1% | 19.21 | 44.7% | 8.1% |
| 35Δ | 19.53 | 10.8% | 1.0% | 19.55 | 46.8% | 7.4% |
| 40Δ | 19.36 | 12.9% | 1.0% | 19.88 | 48.9% | 6.7% |
| 45Δ | 19.19 | 15.0% | 0.9% | 20.21 | 51.0% | 6.1% |
| 50Δ | 19.02 | 17.1% | 0.9% | 20.54 | 53.1% | 5.4% |
| 55Δ | 18.85 | 19.2% | 0.8% | 20.87 | 55.2% | 4.7% |
| 60Δ | 18.68 | 21.3% | 0.7% | 21.20 | 57.3% | 4.0% |
| 65Δ | 18.51 | 23.4% | 0.7% | 21.53 | 59.4% | 3.3% |
| 70Δ | 18.34 | 25.5% | 0.6% | 21.87 | 61.5% | 2.6% |
| 75Δ | 18.17 | 27.6% | 0.6% | 22.20 | 63.6% | 1.9% |
| 80Δ | ||||||
20Δ
- Pseudo strike
- 20.15
- IV
- 6.6%
- B/E move
- 2.0%
- Pseudo strike
- 18.55
- IV
- 40.5%
- B/E move
- 9.5%
25Δ
- Pseudo strike
- 19.86
- IV
- 6.6%
- B/E move
- 1.2%
- Pseudo strike
- 18.88
- IV
- 42.6%
- B/E move
- 8.8%
30Δ
- Pseudo strike
- 19.70
- IV
- 8.7%
- B/E move
- 1.1%
- Pseudo strike
- 19.21
- IV
- 44.7%
- B/E move
- 8.1%
35Δ
- Pseudo strike
- 19.53
- IV
- 10.8%
- B/E move
- 1.0%
- Pseudo strike
- 19.55
- IV
- 46.8%
- B/E move
- 7.4%
40Δ
- Pseudo strike
- 19.36
- IV
- 12.9%
- B/E move
- 1.0%
- Pseudo strike
- 19.88
- IV
- 48.9%
- B/E move
- 6.7%
45Δ
- Pseudo strike
- 19.19
- IV
- 15.0%
- B/E move
- 0.9%
- Pseudo strike
- 20.21
- IV
- 51.0%
- B/E move
- 6.1%
50Δ
- Pseudo strike
- 19.02
- IV
- 17.1%
- B/E move
- 0.9%
- Pseudo strike
- 20.54
- IV
- 53.1%
- B/E move
- 5.4%
55Δ
- Pseudo strike
- 18.85
- IV
- 19.2%
- B/E move
- 0.8%
- Pseudo strike
- 20.87
- IV
- 55.2%
- B/E move
- 4.7%
60Δ
- Pseudo strike
- 18.68
- IV
- 21.3%
- B/E move
- 0.7%
- Pseudo strike
- 21.20
- IV
- 57.3%
- B/E move
- 4.0%
65Δ
- Pseudo strike
- 18.51
- IV
- 23.4%
- B/E move
- 0.7%
- Pseudo strike
- 21.53
- IV
- 59.4%
- B/E move
- 3.3%
70Δ
- Pseudo strike
- 18.34
- IV
- 25.5%
- B/E move
- 0.6%
- Pseudo strike
- 21.87
- IV
- 61.5%
- B/E move
- 2.6%
75Δ
- Pseudo strike
- 18.17
- IV
- 27.6%
- B/E move
- 0.6%
- Pseudo strike
- 22.20
- IV
- 63.6%
- B/E move
- 1.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
SLS
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the…
More →SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The…
More →SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
More →SPRO
Description unavailable
More →SPRY
Description unavailable
More →SRPT
Description unavailable
More →